Table 1. Characteristic of included studies.
NO | Study | Year | Country | Sample size | TP | TN | FP | FN | Cut-off value | Algorithm | Study type | Assay method | Kit used |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Yu D | 2015 | China | 123 | 57 | 46 | 7 | 13 | Ct<45. 0 | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
2 | Jin P | 2015 | China | 476 | 101 | 298 | 43 | 34 | Ct<45. 0 | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
3 | He Q | 2015 | China | 100 | 38 | 48 | 2 | 12 | PMR≥ 4% | NA | Case–control | MethyLight | NA |
4 | He N | 2015 | China | 281 | 54 | 196 | 9 | 22 | Ct<40. 5 | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
5 | Wang Z | 2012 | China | 56 | 25 | 18 | 2 | 11 | PMR≥1% | NA | Case–control | MS-HRM | NA |
6 | Li SJ | 2015 | China | 161 | 66 | 65 | 5 | 25 | NA | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
7 | Wu D | 2016 | China | 1031 | 223 | 697 | 43 | 68 | Ct<45. 0 | 1(1) | Prospective study | RT-PCR | Epipro Colon 2.0 |
8 | Kang Q | 2014 | China | 132 | 60 | 51 | 1 | 20 | NA | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
9 | Ding QQ | 2015 | China | 262 | 60 | 171 | 9 | 22 | Ct<45. 0 | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
10 | Warren JD | 2011 | US, Russia | 144 | 38 | 93 | 1 | 12 | Ct<45. 0 | 2(3) | Case–control | RT-PCR | Epipro Colon 1.0 |
2011 | USA, Russia | 144 | 45 | 83 | 11 | 5 | Ct<41. 0 | 1(3) | Case–control | RT-PCR | Epipro Colon 1.0 | ||
2011 | USA, Russia | 144 | 35 | 94 | 0 | 15 | Ct<45. 0 | 3(3) | Case–control | RT-PCR | Epipro Colon 1.0 | ||
11 | Johnson DA | 2014 | USA | 301 | 74 | 163 | 37 | 27 | NA | NA | Prospective study | RT-PCR | Epipro Colon 1.0 |
12 | Lee HS | 2013 | Korea | 197 | 37 | 87 | 9 | 64 | NA | 1(3) | Case–control | RT-PCR | Abbott Molecular |
13 | Lucia PC | 2014 | USA | 367 | 244 | 20 | 1 | 102 | NA | NA | Case–control | RT-PCR | Epipro Colon 1.0 |
14 | Marc T | 2010 | Germany | 161 | 24 | 98 | 30 | 9 | NA | 2(3) | Case–control | Heavy MethyLight | NA |
2010 | Germany | 161 | 27 | 81 | 47 | 6 | NA | 1(3) | Case–control | Heavy MethyLight | NA | ||
15 | Grutzmann R | 2008 | Germany | 831 | 193 | 403 | 50 | 185 | NA | 2(3) | Case–control | RT-PCR | Epipro Colon 1.0 |
16 | deVos T | 2009 | Germany | 514 | 138 | 282 | 45 | 49 | 3.4ug/L | 1(3) | Case–control | RT-PCR | Epipro Colon 1.0 |
2009 | Germany | 514 | 105 | 316 | 11 | 82 | 3.4ug/L | 2(3) | Case–control | RT-PCR | Epipro Colon 1.0 | ||
17 | Church TR | 2013 | Germany, USA | 1510 | 27 | 1331 | 126 | 26 | Ct<50 | 1(2) | Prospective study | RT-PCR | Epipro Colon 1.0 |
18 | Toth K | 2012 | Hungary | 184 | 73 | 91 | 1 | 19 | Ct<40. 5 | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
2012 | Hungary | 184 | 88 | 78 | 14 | 4 | Ct<40. 5 | 1(3) | Case–control | RT-PCR | Epipro Colon 2.0 | ||
19 | Toth K | 2014 | Hungary | 84 | 30 | 40 | 10 | 4 | PMR≥ 0.01% | NA | Case–control | RT-PCR | Epipro Colon 2.0 |
20 | Su XL | 2014 | China | 234 | 152 | 58 | 4 | 20 | MSP≥1% | NA | Case–control | MSP-DHPLC | NA |
21 | Potter NT | 2014 | USA | 1544 | 30 | 1182 | 318 | 14 | Ct<45. 0 | 1(3) | Prospective study | RT-PCR | Epipro Colon 2.0 |
22 | Lofton-Day C | 2008 | USA | 312 | 92 | 154 | 25 | 41 | NA | NA | Case–control | MethyLight | NA |
23 | He Q | 2010 | China | 352 | 136 | 164 | 6 | 46 | PMR≥ 4% | NA | Case–control | MethyLight | NA |
24 | Ørntoft MW | 2015 | Denmark | 470 | 93 | 282 | 60 | 35 | Ct<45. 0 | 1(3) | Case–control | RT-PCR | Epipro Colon 2.0 |
2015 | Denmark | 470 | 75 | 328 | 14 | 53 | Ct<45. 0 | 2(3) | Case–control | RT-PCR | Epipro Colon 2.0 | ||
25 | Ahlquist DA | 2011 | USA | 100 | 18 | 54 | 16 | 12 | Ct<45. 0 | 1(3) | Case–control | RT-PCR | Epipro Colon 1.0 |
MS-HRM, methylation sensitive high-resolution melting; MSP-DHPLC, methylation spective polymerase chain reaction; RT-PCR, real-time polymerase chain reaction.